ATP1A1 and acute myeloid leukemia: Here, we provided evidence that the ATP1A1/BCL2L1high phenotype is a distinctive clinical feature of these AML subtypes, preserved in VEN-relapsed patients [1] and consistently associated with VEN resistance in the ex vivo drug response [23].